Evaluation of Deformable Image Registration Algorithm for Determination of Accumulated Dose for Brachytherapy of Cervical Cancer Patients
Overview
Authors
Affiliations
Purpose: This study was designed to assess the dose accumulation (DA) of bladder and rectum between brachytherapy fractions using hybrid-based deformable image registration (DIR) and compare it with the simple summation (SS) approach of GEC-ESTRO in cervical cancer patients.
Material And Methods: Patients ( = 137) with cervical cancer treated with 3D conformal radiotherapy and three fractions of high-dose-rate brachytherapy were selected. CT images were acquired to delineate organs at risk and targets according to GEC-ESTRO recommendations. In order to determine the DA for the bladder and rectum, hybrid-based DIR was done for three different fractions of brachytherapy and the results were compared with the standard GEC-ESTRO method. Also, we performed a phantom study to calculate the uncertainty of the hybrid-based DIR algorithm for contour matching and dose mapping.
Results: The mean ± standard deviation (SD) of the Dice similarity coefficient (DICE), Jaccard, Hausdorff distance (HD) and mean distance to agreement (MDA) in the DIR process were 0.94 ±0.02, 0.89 ±0.03, 8.44 ±3.56 and 0.72 ±0.22 for bladder and 0.89 ±0.05, 0.80 ±0.07, 15.46 ±10.14 and 1.19 ±0.59 for rectum, respectively. The median (Q1, Q3; maximum) Gy differences of total D between DIR-based and SS methods for the bladder and rectum were reduced by -1.53 (-0.86, -2.98; -9.17) and -1.38 (-0.80, -2.14; -7.11), respectively. The mean ± SD of DICE, Jaccard, HD, and MDA for contour matching were 0.98 ±0.008, 0.97 ±0.01, 2.00 ±0.70 and 0.20 ±0.04, respectively for large deformation. Maximum uncertainty of dose mapping was about 3.58%.
Conclusions: The hybrid-based DIR algorithm demonstrated low registration uncertainty for both contour matching and dose mapping. The DA difference between DIR-based and SS approaches was statistically significant for both bladder and rectum and hybrid-based DIR showed potential to assess DA between brachytherapy fractions.
Yucheng L, Lingyun Q, Kainan S, Yongshi J, Wenming Z, Jieni D Sci Rep. 2025; 15(1):6800.
PMID: 40000766 PMC: 11861648. DOI: 10.1038/s41598-025-91362-9.
Szlag M, Stankiewicz M, Kellas-Sleczka S, Stapor-Fudzinska M, Cholewka A, Pruefer A Phys Imaging Radiat Oncol. 2024; 31:100631.
PMID: 39262679 PMC: 11387206. DOI: 10.1016/j.phro.2024.100631.
Duprez D, Trauernicht C, Simonds H, Williams O J Appl Clin Med Phys. 2023; 24(8):e13988.
PMID: 37042449 PMC: 10402684. DOI: 10.1002/acm2.13988.
Fu Q, Xie X, Xu Y, Zuo J, Yang X, Xia W J Pers Med. 2023; 13(2).
PMID: 36836556 PMC: 9963278. DOI: 10.3390/jpm13020323.
McDonald B, Zachiu C, Christodouleas J, Naser M, Ruschin M, Sonke J Front Oncol. 2023; 12:1086258.
PMID: 36776378 PMC: 9909539. DOI: 10.3389/fonc.2022.1086258.